Treatment of chronic hepatitis due to hepatitis B virus.
A clearer view of the natural history of chronic hepatitis B virus (HBV) infection has permitted recognition of a phase of viral replication associated with progressive liver damage, and one of absent replication when the disease is inactive and when continued presence of hepatitis B surface antigen (HBs) is due to the integration of viral genes with the host genome. These two phases can be identified by HBe antigenaemia and anti-HBe, respectively. Several active antiviral drugs are available and may significantly benefit certain HBe Ag-positive groups. The antiviral activity of vidarabine and its analogues and of alpha-interferons is established, and insight is being gained into factors that predict response. In general, results depend on duration of infection, and integrity of the patient's immune response. Anti-HBe positive carriers usually need no treatment, but in those with continuing low-level HBV replication or delta superinfection antiviral therapy, although of unproven value, may be tried. In patients without HBV or hepatitis delta virus (HDV) replication who have signs of active disease, immunosuppressants may be tried with benefit.
Sherlock
S
S
Thomas
H C
HC
D000212:Acyclovir / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006509:Hepatitis B / Q000175:diagnosis / Q000188:drug therapy* / Q000628:therapy; D006510:Hepatitis B Antibodies / Q000032:analysis; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006513:Hepatitis B e Antigens / Q000032:analysis; D003699:Hepatitis D / Q000628:therapy; D006521:Hepatitis, Chronic / Q000188:drug therapy* / Q000628:therapy; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use; D014740:Vidarabine / Q000627:therapeutic use
D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D007370:Interferon Type I; D014740:Vidarabine; D000212:Acyclovir